Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:48 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 4,129 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Neck Neoplasms Clear all

Conditions: Cancer
Interventions: cyclophosphamide, Cryoablation; Drug · Device
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 120 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Head and Neck Cancer
Interventions: Cisplatin or carboplatin, Intensity-modulated radiation therapy (IMRT) or Intensity-modulated proton therapy (IMPT), Pembrolizumab, LymphDetect assay, Surgery +/- neoadjuvant pembrolizumab; Drug · Radiation · Diagnostic Test + 1 more
Lead sponsor: Kevin Contrera; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Head and Neck Cancer
Interventions: porfimer sodium, fluorophotometry; Drug · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1995
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Esophageal Cancer, Gastric Cancer
Interventions: G17DT Immunogen, cisplatin, fluorouracil; Biological · Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Esophageal Cancer, Gastric Cancer, Liver Cancer
Interventions: fluorouracil, irinotecan hydrochloride, leucovorin calcium, vorinostat, pharmacological study; Drug · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Cervical Squamous Cell Carcinoma, Recurrent Cervical Cancer
Interventions: bevacizumab, laboratory biomarker analysis; Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Head and Neck Cancer
Interventions: Pemetrexed plus Gemcitabine; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Solid Tumor, Advanced Solid Tumor
Interventions: CHS-114, Toripalimab, 5 Fluorouracil, Cisplatin; Drug
Lead sponsor: Coherus Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 20
States / cities: Tucson, Arizona • Duarte, California • Aurora, Colorado + 16 more

Conditions: Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Nasopharyngeal Squamous Cell Carcinoma, Metastatic Oral Cavity Squamous Cell Carcinoma, Metastatic Oropharyngeal Squamous Cell Carcinoma, Metastatic Sinonasal Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Nasopharyngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Recurrent Sinonasal Squamous Cell Carcinoma, Squamous Cell Carcinoma of Unknown Primary, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Sinonasal Cancer AJCC v8
Interventions: Autologous Tumor Membrane Vesicles Vaccine, Biospecimen Collection, Computed Tomography, Echocardiography, Magnetic Resonance Imaging, Pembrolizumab, Positron Emission Tomography, Surgical Procedure; Biological · Procedure
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Colorectal Cancer, Head and Neck Cancer
Interventions: Nilotinib + Cetuximab; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Head And Neck Cancer
Interventions: Acupuncture - Group 1, Acupuncture - Group 2, Standard Care, Questionnaire; Procedure · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 435 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Head and Neck Cancer (H&N), Oral Mucositis (Ulcerative) Due to Radiation, Stomatitis (Oral Mucositis), Xerostomia Due to Radiotherapy, Radiation Toxicity
Interventions: ORAL CARE PRODUCT KIT; Other
Lead sponsor: UNCANCER LLC; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Clearwater, Florida

Conditions: Cervical Carcinoma
Interventions: Non-Interventional Study; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 21 Years to 65 Years · Female only
Enrollment: 2,216 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Head and Neck Squamous Cell Cancer
Interventions: Cetuximab, BYL719, IMRT (Intensity-Modulated Radiation Therapy); Drug · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 6
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more

Conditions: Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7
Interventions: Cetuximab, Intensity-Modulated Radiation Therapy, Ipilimumab, Laboratory Biomarker Analysis; Biological · Radiation · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Papillary Thyroid Cancer, Follicular Thyroid Cancer, Huerthle Cell Thyroid Cancer, Renal Cell Carcinoma
Interventions: rosiglitazone, XL184; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 5
States / cities: Duarte, California • Boston, Massachusetts • The Bronx, New York + 2 more

Conditions: STD
Interventions: Not listed
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 18 Years to 26 Years
Enrollment: 550 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Ampullary Cancer, Duodenal Cancer, Bile Duct Cancer, Bile Duct Disorders, Gallstones, Obstructive Jaundice, Pancreatic Disorders (Noncancerous), Colorectal Cancer, Esophageal Cancer, Barrett's Esophagus, Gastric Malignancies, Pancreatic Cancer, Pediatric Gastroenterology, Cholangiocarcinoma, Pancreatic Pseudocysts, Acute and Chronic Pancreatitis, Recurrent Pancreatitis, Cholangitis, Bile Leak, Biliary Strictures, Pancreatic Divisum, Biliary and Pancreatic Stones, Choledocholithiasis
Interventions: Interventional Endoscopy; Procedure
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 12,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Head And Neck Cancer
Interventions: Questionnaires & Study Visit; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 361 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Head and Neck Cancer
Interventions: TAK-981, Cetuximab, Avelumab, TAK-981 + Cetuximab, TAK-981 + Avelumab; Drug · Biological · Combination Product
Lead sponsor: Presage Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 6
States / cities: Ann Arbor, Michigan • New York, New York • North New Hyde Park, New York + 2 more

Conditions: Barrett Esophagus, Esophageal Cancer
Interventions: Not listed
Lead sponsor: Ochsner Health System; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Kenner, Louisiana

Conditions: Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Lung Carcinoma, Malignant Digestive System Neoplasm, Malignant Solid Neoplasm
Interventions: Computer-Assisted Intervention, Patient Monitoring, Questionnaire Administration; Other · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Malignant Head and Neck Neoplasm, Mucositis, Radiation-Induced Disorder
Interventions: Educational Intervention, Gabapentin, Pain Therapy, Quality-of-Life Assessment, Questionnaire Administration, Oxycodone/Acetaminophen, Hydrocodone/Acetaminophen, Fentanyl, Ibuprofen, Magic Mouthwash; Other · Drug
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Head and Neck Cancer, Lung Cancer
Interventions: zileuton; Drug
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Detroit, Michigan

Search by objective public record fields.

Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer

Circulating Tumor DNA-Informed Adjuvant Therapy for Intermediate-Risk Head and Neck Cancer

Porfimer Sodium in Diagnosing Patients With Head and Neck Cancer

Vaccine Therapy Plus Chemotherapy in Treating Patients With Metastatic or Locally Recurrent Stomach Cancer or Esophageal Cancer

Vorinostat, Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Upper Gastrointestinal Cancer

Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix

A Phase II Study of Pemetrexed Plus Gemcitabine for Metastatic/Recurrent Head and Neck Cancer (HNSCC)

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer

A Phase I Study of Nilontinib and Cetuximab in Patients With Solid Tumors

Controlled Trial Of Acupuncture To Prevent Radiation-Induced Xerostomia

Oral Care Program for Mouth Side Effects During Head and Neck Radiation Therapy

Barriers to Cervical Cancer Screening

Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC)

Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer

A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors

Study of Oral Papillomavirus In Teens and Twenties

Interventional Endoscopy Database for Pancreatico-biliary, Gastrointestinal and Esophageal Disorders

Spousal Support in Head and Neck Cancer

Intratumoral Microdosing of TAK-981 in Head and Neck Cancer

Microbiome Involvement With Barrett's Esophagus and Progression to Esophageal Adenocarcinoma

Remote Monitoring in Cancer Care: A Platform Study

Gabapentin Compared to Standard of Care in Preventing Mucositis in Patients With Stage III-IV Head and Neck Cancer Undergoing Primary or Adjuvant Chemoradiation Therapy

Zileuton in Preventing Lung Cancer in Patients With Bronchial Dysplasia